Breast cancer treatment is currently limited by the inability to accurately define the subset of patients at high risk of recurrence or those who are Likely to respond well to a given form of adjuvant treatment. A complex array of molecular markers are now under investigation as potential indicators of prognosis or treatment response. Currently. the clinical significance of most of these factors is not well characterized, although a number have exhibited promising associations with breast cancer. As a means of enhancing the ability of Lombardi Cancer Center (LCC) scientists to carry out prognostic and predictive research on promising and novel molecules, we have established the Breast Cancer Serum Bank Core Facility (SBCF). The Breast Cancer Serum Bank (SBCF) core facility is responsible for maintaining and expanding a bank of sequential serum, plasma, and lymphocyte samples linked to a computer database with associated clinical and follow-up data. The core facility provides SPORE investigators with access to patient samples and consultation for design of molecular clinical correlation studies. The SBCF includes samples from breast cancer patients, and healthy women with a normal or high risk of breast cancer. The core facility allows molecules under investigation by SPORE researchers to be evaluated clinically as markers of early breast cancer, tumor burden, and for predicting response to specific therapies. Measuring such markers in plasma or serum as opposed to tumor tissue allows the serial measurements to be made during the course of treatment and follow-up. Serial changes in marker values from baseline can be correlated with disease progression and treatment failure. Once tests become available for determining carrier status for breast cancer predisposing mutations (e.g. BRCA1), the lymphocyte samples will be extremely valuable for studying the pathogenesis of irritable breast cancer. The SBCF was initially funded as a component of the Clinical Breast Cancer Research Core in the LCC Breast Cancer SPORE in 1992. At the time it was newly developed resource, with samples to be obtained from new and continuing LCC patients. Subsequent to the funding of the LCC SPORE, an extensive serum/plasma bank and clinical database with serial samples and long-term follow up on more than 1500 patients was acquired from the University of Wisconsin Cancer Center (UWCC) (described more fully in Section 5). Because of the large size and comprehensive nature of the UWCC serum bank, the scope of operations of the SBCF increased considerably, necessitating the establishment of the SBCF as a separate core facility. It 115 a primary goal of the SBCF to make the samples and the associated database accessible and available to other breast cancer SPORE centers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA058185-08S3
Application #
6499553
Study Section
Project Start
1999-09-14
Project End
2003-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
8
Fiscal Year
2001
Total Cost
$135,290
Indirect Cost
Name
Georgetown University
Department
Type
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Sharif, G M; Schmidt, M O; Yi, C et al. (2015) Cell growth density modulates cancer cell vascular invasion via Hippo pathway activity and CXCR2 signaling. Oncogene 34:5879-89
Rosenfield, Sonia M; Bowden, Emma T; Cohen-Missner, Shani et al. (2012) Pleiotrophin (PTN) expression and function and in the mouse mammary gland and mammary epithelial cells. PLoS One 7:e47876
Wellstein, Anton; Toretsky, Jeffrey A (2011) Hunting ALK to feed targeted cancer therapy. Nat Med 17:290-1
Hu, Zhang-Zhi; Kagan, Benjamin L; Ariazi, Eric A et al. (2011) Proteomic analysis of pathways involved in estrogen-induced growth and apoptosis of breast cancer cells. PLoS One 6:e20410
Stylianou, D C; Auf der Maur, A; Kodack, D P et al. (2009) Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor. Oncogene 28:3296-306
Coticchia, Christine M; Revankar, Chetana M; Deb, Tushar B et al. (2009) Calmodulin modulates Akt activity in human breast cancer cell lines. Breast Cancer Res Treat 115:545-60
Gibby, Krissa A; McDonnell, Kevin; Schmidt, Marcel O et al. (2009) A distinct role for secreted fibroblast growth factor-binding proteins in development. Proc Natl Acad Sci U S A 106:8585-90
Deb, Tushar B; Coticchia, Christine M; Barndt, Robert et al. (2008) Pregnancy-upregulated nonubiquitous calmodulin kinase induces ligand-independent EGFR degradation. Am J Physiol Cell Physiol 295:C365-77
Veselik, David J; Divekar, Shailaja; Dakshanamurthy, Sivanesan et al. (2008) Activation of estrogen receptor-alpha by the anion nitrite. Cancer Res 68:3950-8
Bullitt, Elizabeth; Lin, Nancy U; Smith, J Keith et al. (2007) Blood vessel morphologic changes depicted with MR angiography during treatment of brain metastases: a feasibility study. Radiology 245:824-30

Showing the most recent 10 out of 117 publications